Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Mastering the Computational Challenges of Elispot Plate Evaluation.

Janetzki S.

Methods Mol Biol. 2018;1808:9-30. doi: 10.1007/978-1-4939-8567-8_2.

PMID:
29956170
2.

A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis.

Swartz AM, Reap E, Norberg P, Schmittling R, Janetzki S, Sanchez-Perez L, Sampson JH.

J Immunol Methods. 2018 Aug;459:90-93. doi: 10.1016/j.jim.2018.05.015. Epub 2018 May 31.

3.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

4.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:76. eCollection 2016. Review.

5.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. Review.

6.

Enzyme-Linked ImmunoSpot (ELISpot) for Single-Cell Analysis.

Janetzki S, Rabin R.

Methods Mol Biol. 2015;1346:27-46. doi: 10.1007/978-1-4939-2987-0_3.

PMID:
26542713
7.

Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and Fluorospot assay.

Janetzki S.

J Immunother Cancer. 2015 Jul 21;3:30. doi: 10.1186/s40425-015-0074-0. eCollection 2015. No abstract available.

8.

Guidelines for the automated evaluation of Elispot assays.

Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A.

Nat Protoc. 2015 Jul;10(7):1098-115. doi: 10.1038/nprot.2015.068. Epub 2015 Jun 25.

PMID:
26110715
9.

Correction: Santos, R.S., et al. Improvement of IFNγ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. Cells 2015, 4, 1-18.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2015 Apr 21;4(2):133-4. doi: 10.3390/cells4020133.

10.

Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2014 Dec 24;4(1):1-18. doi: 10.3390/cells4010001. Erratum in: Cells. 2015;4(2):133-4.

11.

Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays.

Janetzki S, Rueger M, Dillenbeck T.

Cells. 2014 Nov 27;3(4):1102-15. doi: 10.3390/cells3041102.

12.

The role of the reporting framework MIATA within current efforts to advance immune monitoring.

Janetzki S, Britten CM; MIATA Core Team.

J Immunol Methods. 2014 Jul;409:6-8. doi: 10.1016/j.jim.2014.05.003. Epub 2014 May 9. No abstract available.

PMID:
24816466
13.

Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.

Patton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, Esser MT, Woo J, Janetzki S, Cherukuri A.

Clin Vaccine Immunol. 2014 May;21(5):628-35. doi: 10.1128/CVI.00736-13. Epub 2014 Feb 26.

14.

Immunological Monitoring to Rationally Guide AAV Gene Therapy.

Britten CM, Walter S, Janetzki S.

Front Immunol. 2013 Sep 12;4:273. doi: 10.3389/fimmu.2013.00273. Review.

15.

Structured reporting of T cell assay results.

Janetzki S, Hoos A, Melief CJ, Odunsi K, Romero P, Britten CM.

Cancer Immun. 2013 Jul 15;13:13. Print 2013. No abstract available.

16.

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).

McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S.

Cytometry A. 2013 Aug;83(8):728-38. doi: 10.1002/cyto.a.22319. Epub 2013 Jun 20.

17.
18.

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.

Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM.

Cancer Immunol Immunother. 2013 Apr;62(4):615-27. doi: 10.1007/s00262-012-1359-5. Epub 2012 Nov 9.

19.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

20.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

21.

Harmonization of immune biomarker assays for clinical studies.

van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A.

Sci Transl Med. 2011 Nov 9;3(108):108ps44. doi: 10.1126/scitranslmed.3002785. Review.

PMID:
22072636
22.

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Moodie Z, Price L, Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:185-96. doi: 10.1007/978-1-61779-325-7_15.

PMID:
21956511
23.

The impact of harmonization on ELISPOT assay performance.

Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:25-36. doi: 10.1007/978-1-61779-325-7_2.

PMID:
21956498
24.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group.

J Transl Med. 2011 Jul 11;9:108. doi: 10.1186/1479-5876-9-108.

25.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.

26.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM.

Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16.

27.

Improved endpoints for cancer immunotherapy trials.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8. Review.

28.

Response definition criteria for ELISPOT assays revisited.

Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.

29.

Training in immunology of relevance to global health issues in resource poor settings.

Parida SK, Magalhaes I, Dubois P, Janetzki S.

Eur J Immunol. 2010 May;40(5):1228-31. doi: 10.1002/eji.201090022. No abstract available.

30.

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A.

Cancer Immunol Immunother. 2010 Apr;59(4):609-18. doi: 10.1007/s00262-009-0788-2. Epub 2009 Nov 6.

31.

"MIATA"-minimal information about T cell assays.

Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM.

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.

32.

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group.

Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4.

33.

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.

34.

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A.

Cancer Immunol Immunother. 2008 Mar;57(3):285-8. Epub 2007 Aug 25. No abstract available.

35.

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).

Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group.

Cancer Immunol Immunother. 2008 Mar;57(3):303-15. Epub 2007 Aug 25.

36.

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma.

Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK, Brennan MF.

Dig Dis Sci. 2007 Aug;52(8):1964-72. Epub 2007 Apr 10.

PMID:
17420942
37.

Measurement of cytokine release at the single cell level using the ELISPOT assay.

Cox JH, Ferrari G, Janetzki S.

Methods. 2006 Apr;38(4):274-82.

PMID:
16473524
38.

Standardization and validation issues of the ELISPOT assay.

Janetzki S, Cox JH, Oden N, Ferrari G.

Methods Mol Biol. 2005;302:51-86.

PMID:
15937345
39.

Evaluation of Elispot assays: influence of method and operator on variability of results.

Janetzki S, Schaed S, Blachere NE, Ben-Porat L, Houghton AN, Panageas KS.

J Immunol Methods. 2004 Aug;291(1-2):175-83.

PMID:
15345315
40.

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH.

J Immunol Methods. 2002 Feb 1;260(1-2):157-72.

PMID:
11792386
41.

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study.

Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK.

Int J Cancer. 2000 Oct 15;88(2):232-8.

42.

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.

Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN.

Int J Cancer. 2000 Aug 1;87(3):391-8.

43.

Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay.

Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN.

J Immunol Methods. 2000 Feb 3;234(1-2):1-12.

PMID:
10669764
44.

MHC polymorphism can enrich the T cell repertoire of the species by shifts in intrathymic selection.

Dyall R, Messaoudi I, Janetzki S, Nikolic-Zugić J.

J Immunol. 2000 Feb 15;164(4):1695-8.

45.

A new hotspot for cancer immunotherapy?

Lewis JJ, Janetzki S.

Cancer J Sci Am. 1998 Sep-Oct;4(5):298-9. No abstract available.

PMID:
9815292
46.
47.

Heat shock protein vaccines against cancer.

Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK.

J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):352-6.

PMID:
8280719
48.

Structure of the mRNA and of the gene coding for the rabbit erythroid 15-lipoxygenase.

Thiele BJ, Fleming J, Chester J, O'Prey J, Prehn S, Janetzki S, Rapoport SM, Harrison PR.

Biomed Biochim Acta. 1990;49(2-3):S17-24.

PMID:
2386503
49.

The promoter structure and complete sequence of the gene encoding the rabbit erythroid cell-specific 15-lipoxygenase.

O'Prey J, Chester J, Thiele BJ, Janetzki S, Prehn S, Fleming J, Harrison PR.

Gene. 1989 Dec 14;84(2):493-9.

PMID:
2612916
50.

The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases.

Fleming J, Thiele BJ, Chester J, O'Prey J, Janetzki S, Aitken A, Anton IA, Rapoport SM, Harrison PR.

Gene. 1989 Jun 30;79(1):181-8.

PMID:
2777088

Supplemental Content

Loading ...
Support Center